Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 7/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.50 |
| ▸ | CCR2 | P41597 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7516953 | 0.83 | DRD4 (0.48) | — | |
| SCHEMBL7464246 | 0.81 | ROCK1 (0.54) | ROCK1ROCK2CCR2KCNH2MCHR1 | |
| SCHEMBL7464417 | 0.81 | ROCK1 (0.54) | ROCK1ROCK2CCR2KCNH2MCHR1 | |
| SCHEMBL10609088 | 0.79 | HRH3 (0.53) | ROCK1ROCK2CCR2KCNH2MCHR1 | |
| SCHEMBL10607825 | 0.79 | HRH3 (0.62) | ROCK1ROCK2CCR2MCHR1HRH3 | |
| Hydrochloric Acid SCHEMBL10607374 | 0.78 | SMN1; SMN2 (0.54) | ROCK1ROCK2CCR2KCNH2MCHR1 | |
| SCHEMBL10608592 | 0.78 | HRH3 (0.59) | ROCK1ROCK2CCR2KCNH2MCHR1 | |
| SCHEMBL7460334 | 0.78 | UTS2R (0.45) | — | |
| SCHEMBL10607229 | 0.77 | OPRK1 (0.56) | ROCK1ROCK2CCR2KCNH2MCHR1 | |
| SCHEMBL4785850 | 0.77 | ROCK1 (0.54) | ROCK1ROCK2CCR2KCNH2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | LIN NAN-HORNG (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1212319-A2 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019817-A2 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | GAP43, SLC18A2, GABRE | ROCK1 3162/4885ROCK2 2792/4885CCR2 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.